Kairos Pharma Ltd(KAPA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:58 PM ET (Korea 10/31 05:58)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.95 | Insider Own | 33.61% | Shs Outstand | 3.1M | Perf Week | -5.1% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | -81.08% | Insider Trans | - | Shs Float | 2.3M | Perf Month | -66.03% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.63 | Inst Own | 3.9% | Short Float | 5.98% | Perf Quarter | -75.58% |
| Income | -0.01B | P/S | - | EPS this Y | -23.33% | Inst Trans | 7.84% | Short Ratio | 0.36 | Perf Half Y | -86.65% |
| Sales | 0.00B | P/B | 0.39 | EPS next 5Y | - | ROA | -104.32% | Short Interest | 0.13M | Perf YTD | -89.34% |
| Book/sh | 1.37 | P/C | 0.68 | EPS past 3/5Y | -53.5% -29.28% | ROE | -113.96% | 52W High | -93.39% ($8.02) | Perf Year | -93.36% |
| Cash/sh | 0.78 | P/FCF | - | Sales past 3/5Y | - | ROIC | -138.51% | 52W Low | 1.63% ($0.52) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.64% | Gross Margin | - | Volatility(W/M) | 7.31% 17.86% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.98 | EPS Q/Q | 21.56% | Profit Margin | - | RSI (14) | 19.74 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.98 | Sales Q/Q | - | SMA20 | -26.93% ($0.73) | Beta | 1.51 | Target Price | $49 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -60.02% ($1.33) | Rel Volume | 0.13 | Prev Close | $0.54 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -82.6% ($3.05) | Avg Volume(3M) | 0.37M | Price | $0.53 |
| IPO | 2024/9/16 | Option/Short | No/Yes | Trades | 218 | Volume | 47,420 | Change | -1.87% |
🧬 Kairos Pharma is a clinical-stage biotech focused on developing anticancer drugs that target cancer cells' drug resistance and immune evasion mechanisms. ENV-105, an antibody that blocks CD105 to overcome resistance, is being developed in castration-resistant prostate cancer (Phase 2) and EGFR-mutant lung cancer (Phase 1), while KROS-101, a small molecule that acts as a GITR ligand, is being developed as a differentiated immuno-oncology candidate at the preclinical stage.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 13% of its average volume.
KAPA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -23.3% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #583 of 597 in the industry
Based on market cap of $2M.
PPBT#579 Purple Biotech Ltd ADR $2M PER - 
GNPX#581 Genprex Inc $2M PER - 
XRTX#582 XORTX Therapeutics Inc $2M PER - KAPA#583 Kairos Pharma Ltd $2M PER - 
GOVX#584 Geovax Labs Inc $2M PER - 
FAQ
What kind of company is KAPA?
KAPA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KAPA?
The market cap of KAPA is approximately $2M, ranking 5,816 within its sector.
What is the 52-week high and low for KAPA?
KAPA has recorded a 52-week high of $8.02 and a low of $0.52.
